Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: A randomized, placebo-controlled trial
- 1 March 1995
- journal article
- clinical trial
- Published by Elsevier BV in The Journal of Pediatrics
- Vol. 126 (3), 421-426
- https://doi.org/10.1016/s0022-3476(95)70462-0
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Direct evidence for erythropoietin-induced release of endothelin from peripheral vascular tissueLife Sciences, 1994
- A randomized, double-blind, placebo-controlled trial of recombinant erythropietin in treatment of the anemia of bronchopulmonary dysplasiaThe Journal of Pediatrics, 1993
- BQ123, an ETA Receptor Antagonist, Attenuates Endothelin-1-Induced Vasoconstriction in Rat Pulmonary CirculationJournal of Cardiovascular Pharmacology, 1993
- Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infantsThe Journal of Pediatrics, 1992
- Relationship between determinants of oxygen delivery and respiratory abnormalities in preterm infants with anemiaThe Journal of Pediatrics, 1992
- Erythropoietin affects the maturation pattern of fetal G-CSF-responsive progenitorsAmerican Journal of Hematology, 1992
- Recombinant erythropoietin compared with erythrocyte transfusion in the treatment of anemia of prematurityThe Journal of Pediatrics, 1991
- Sepsis associated with transfusion of red cells contaminated with Yersinia enterocoliticaTransfusion, 1990
- Anemia of prematurity: Determinants of the erythropoietin responseThe Journal of Pediatrics, 1984
- Decreased response of plasma immunoreactive erythropoietin to “available oxygen” in anemia of prematurityThe Journal of Pediatrics, 1984